Skan Group Ag · SIX:SKAN
Skan — Investor Day (May 2025)
76 slides from Skan's investor day presentation, May 2025
Slide 1: SKAN Group AG Capital Markets Day
SKAN Group AG Capital Markets Day May 2025 1
Slide 2: May 2025
May 2025
Slide 3: Disclaimer
SKAN Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. Th
Slide 4: Welcome to SKAN Capital Markets Day: Our speakers
SKAN Welcome to SKAN Capital Markets Day Our speakers Thomas Philippe Burim Marina Thomas Ralf Richard Huber Jérôme Maraj Häni Zinn Krämer Denk (CEO) (CMO) (CFO) (CPCO) (COAMS) (CTO) (Senior consultant) May 2025 SKAN Group AG Capital Markets Day 4
Slide 5: Overview of presentations
SKAN SKAN capital markets day Overview of presentations Time Topic Speaker 09:00 – 09:10 Welcome Thomas Huber 09:10 – 09:30 Industry trends & SKAN strategy 2030 Thomas Huber 09:30 – 09:50 Growth path, margin expansion and targets Burim Maraj 09:50 – 10:10 Competitive landscape & technology partners
Slide 6: Industry trends & SKAN strategy 2030
SKAN Group AG Capital Markets Day Industry trends & SKAN strategy 2030 Thomas Huber, Group CEO May 2025 6
Slide 7: Growth drivers for the biopharmaceutical market
SKAN Growth drivers for the biopharmaceutical market Growing chronical Progress in Growing field of diseases Biotechnology applications Demographic trends and live style of todays Improvement in lab technology and Growing number of available drugs that population are promoting chronical computer sci
Slide 8: Growth drivers for isolators in fill-finish
SKAN Growth drivers for isolators in fill-finish Sterility and Isolator – Complex molecules correct dose technology of choice Complex molecules are difficult and Containment during manufacturing is key Isolator technology provides the highest expensive to produce to keep the drug sterile and to prot
Slide 9: Resulting growth drivers for SKAN
SKAN Resulting growth drives for SKAN Supported by the growing number of molecules in development and clinical phases Double digit growth of underlying biologics market. The growing installed base provides a growing opportunity for services, spare parts and retro fits With robotics we are expanding
Slide 10: SKAN Strategy 2030
SKAN SKAN Strategy 2030 SKAN’s Strategy 2030 will Fortify market leadership in our core markets Expand our offering within our niche with new processes and consumables continue to strengthen our position in the market Stay inside our “niche” …. Culture – Quality – GMP Increase customer attractivenes
Slide 11: Pre-approved services
SKAN Pre-approved services May 2025 SKAN Group AG Capital Markets Day
Slide 12: Growth path, margin expansion and targets
SKAN Group AG Capital Markets Day Growth path, margin expansion and targets Burim Maraj, Group CFO May 2025 12
Slide 13: SKAN's growth path
SKAN‘s growth path SKAN 1 Excellent track-record with consistent above-market growth Persistent structural growth factors fuel the continued strong 2 performance, reflected in double-digit growth rates Net sales growth underpinned by a strong core business and 3 further accelerated by strategic init
Slide 14: Excellent track-record with consistent above-market growth and increasing profitability
SKAN Excellent track-record with consistent above-market growth and increasing profitability Net sales & order intake EBITDA (CHFm) EBITDA (CHFm) and EBITDA margin (%) Consistent, above-market net sales growth (+17.2 CAGR 2020-2024) 201.1 280.3 411.7 295.1 359.5 +129 +132 +165 +216 +83 Strong revenu
Slide 15: Expand market leadership & remain #1
«…four – three – two – one» ignition and lift-off! SKAN FTE’s Expand market leadership & remain…. EBITDA Net sales No. ~4x ~3x ~2x #1 Structural key drivers of SKAN’s growth course Century of biology / Growth of Regulatory Personalized medicine Technology shift Injectables (bio)- pharma environment
Slide 16: Net sales growth underpinned by strong core business and strategic initiatives
SKAN Net sales growth underpinned by a strong core business and further accelerated by strategic initiatives Growth contributors (1) Net sales by strategic planets & reporting segments Comments (CHFm) (in % of total net sales) E&S Strategic goal: balanced revenue mix Core S&C to reduce volatility an
Slide 17: Margin expansion by integrated process solutions and high margin services
SKAN Margin expansion by integrated process solutions and new high margin services and consumables EBITDA margin contribution (1) EBITDA by strategic planets & reporting segments Comments (in % of net sales) (in % of total EBITDA) Strategic goal: drive >50% of E&S Gradually increase Core S&C EBITDA
Slide 18: SKAN continues to invest significantly in its future growth
SKAN SKAN continues to invest significantly in its future growth Investment split by regions Further capital allocation • Vision and Objectives M&A SKAN is committed to invest significantly in its Switzerland 2% future growth beyond the mid-term guidance. Germany Opportunistic M&A strategy mainly ba
Slide 19: Financial targets and guidance
SKAN Financial targets and guidance 2025 Guidance (1) Confirmed Mid-term Targets 1 Group net sales growth Mid-teens Mid- to upper teens (2) av 2 Segment net sales growth E&S S&C E&S S&C Gradually increase profitability level to 3 EBITDA margin 14 - 16% upper teens in the mid-term. Potential for furt
Slide 20: Competitive landscape and technology partners
SKAN Group AG Capital Markets Day Competitive landscape and technology partners Philippe Jérôme, Chief Sales and Marketing Officer May 2025 20
Slide 21: SKAN's leadership position is underpinned by high entry barriers and value proposition
SKAN’s leadership position is underpinned by high SKAN entry barriers and compelling value proposition Entry barriers SKAN’s value proposition Key purchasing criteria Product quality / reliability Technological Mastery of difficult to replicate know-how on edge highest-performance isolators Brand re
Slide 22: Technological edge & innovation
SKAN Technological edge & innovation HVAC engineering Fabrication know-how Electron beam transfer Filling technology & air flow modelling Simplicity in the design for fast start up Robust technology for longer production availability GMP documentation & Chemical know-how on cleaning qualification of
Slide 23: Highest quality & service support
SKAN Highest quality & service support User Management Container Holistic aseptic processing expertise «SKAN like» expectation Quality by Design Process Validation Automation of the process to reduce human intervention Improved interaction Life cycle Management Data Management system to facilitate t
Slide 24: SKAN is focused on high value isolators, the premium segment
SKAN SKAN is focused on high value isolators, in particular the premium high-value segment of the market Competitive landscape(1) Offer best-in-class high value isolators Premium high- and complementary accessories value players Have formed partnerships to provide Premium integrated solutions high-v
Slide 25: Trusted and long-standing relationships to a broad base of partners
SKAN Trusted and long-standing relationships to a broad base of partners Solutions for filling Production lines for Machinery and Packaging of and sealing processing of bottles, advanced process pharmaceutical different containers vials, ampoules, technology supplier for products in blisters, such a
Slide 26: Future outlook & innovation initiatives
SKAN Future outlook & innovation initiatives Flexible solutions for a range of aseptic process handling applications Robotics and Automated robotics offer a high level of processes data robustness, i.e. more reproducible and accurate management for integrated Robotic systems ofter significant time e
Slide 27: SKAN Culture and Managing Growth
SKAN Group AG Capital Markets Day SKAN Culture and Managing Growth Marina Häni, Chief People & Culture Officer May 2025 27
Slide 28: SKAN culture and managing growth
SKAN SKAN culture and managing growth Culture Growth Retention May 2025 SKAN Group AG Capital Markets Day 28
Slide 29: The unique SKAN culture as a success factor
SKAN The unique SKAN culture as a success factor Culture is not a buzzword - it is our strategic advantage. It empowers growth, fosters innovation, and creates loyalty. At SKAN, we have made it our mission to nurture this culture, because we know: Companies don’t build culture - people do! May 2025
Slide 30: SKAN culture
SKAN SKAN culture At SKAN, we look for people who fit our culture - not just the job description. Our work culture plays a decisive role in fostering motivation, collaboration, and commitment. It’s what attracts people who bring both the technical skills and the right mindset. May 2025 SKAN Group AG
Slide 31: Our values and culture
SKAN Our values and culture May 2025 SKAN Group AG Capital Markets Day 31
Slide 32: SKAN culture survey - What our employees say
SKAN SKAN culture survey - What our employees say Survey results on SKAN`s corporate culture 70 66 59 60 57 51 51 50 50 46 Number of mentions 40 40 39 39 39 38 40 36 34 32 31 30 30 27 27 26 26 25 25 25 23 22 22 21 21 20 20 19 19 19 20 10 0 May 2025 SKAN Group AG Capital Markets Day 32
Slide 33: Empowering growth through dedicated people
SKAN Empowering growth through dedicated people Ø 145 new colleagues/year Loyal, increasing workforce (1) Headcount 1’471 1,471 Headcount still with SKAN today 1’388 83 216 1’172 165 81.1% 132 746 129 76.4% 77.7% 371 203 71.7% 56.7% 2019 2020 2021 2022 2023 2024 Total 2010 2015 2022 2023 2024 May 20
Slide 34: Managing growth
SKAN Managing growth Location advantage and global reach Good candidate experience in the recruiting process culture as a key Factor in recruitment In house active sourcing via LinkedIn SKAN academy & onboarding Some of the 2024 entries from Allschwil Strong employer branding and strengthening of th
Slide 35: Talent acquisition – our differentiators
Talent aquisition – our differentiators SKAN Unique SKAN culture We had several appearances that strengthened our Modern working employer brand environment Reconnecting with alumni High-visibility events Job fair visits Training of apprentices Meet & Eat and trainees Collaboration with universities
Slide 36: Some impressions of our talent acquisition activities
SKAN Some impressions of our talent aquisition activities May 2025 SKAN Group AG Capital Markets Day 36
Slide 37: Environment Built for Innovation and Belonging
SKAN Environment Built for Innovation and Belonging We design our physical and virtual working environment and continuously improve it to create a pleasant and productive working environment. “The open contact and “l enjoy working at SKAN 'l enjoy the way we work helpfulness at all levels create bec
Slide 38: Retention – a key to sustainable growth
Retention – SKAN a key to sustainable growth Hiring the right people is only one part. Keeping them is just as important. Attractive work environment Competitive benefits Employee engagement and feedback Career development Leadership development May 2025 SKAN Group AG Capital Markets Day 3838
Slide 39: Benefits that strengthen our team and culture
SKAN Benefits that strengthen our team and culture Trainings at the Modern International Flextime Homeoffice SKAN Academy Structured workplace team onboarding and more… Health & Employee Free drinks Free work- and Celebrating sport program discounts and fruits SKAN-wear success May 2025 SKAN Group A
Slide 40: Fostering engagement through open dialogue
SKAN Fostering engagement through open dialogue We conduct regular employee surveys and actively respond to employee feedback. Their concerns are taken seriously and included in our decision-making processes. Certified Certified Certified Certified Certified OCT 2024 – OCT 2025 OKT 2024 – OKT 2025 O
Slide 41: Career development
SKAN Career development Internal mobility First-time leadership Continuous learning May 2025 SKAN Group AG Capital Markets Day 41
Slide 42: Leadership development
SKAN Leadership development Management leadership program Individual coaching Focus on people May 2025 SKAN Group AG Capital Markets Day 42
Slide 43: Some impressions of our culture
SKAN Some impressions of our culture May 2025 SKAN Group AG Capital Markets Day 43
Slide 44: Questions & answers
Questions & answers May 2025 44
Slide 45: Coffee break
Coffee break May 2025 45
Slide 46: Isolator technology and standardization
SKAN Group AG Capital Markets Day Isolator technology and standardization Ralf Krämer, Chief Technology Officer May 2025 46
Slide 47: Key challenge for (bio-)pharmaceutical products
SKAN Key challenge for (bio-)pharmaceutical products Key challenge Products In particular true for Medical safety Injectables High-value biopharma drugs Medication safety is key and (cross-) Cancer drugs (Antibody Drug Risk of significant economic losses contamination unacceptable Conjugates (ADC),
Slide 48: Isolators – Mission critical for (bio-)pharmaceutical processes
Isolators – Mission critical for (bio-)pharmaceutical SKAN processes Solution: Medication sterility CLEANROOM + Filling / closing in cleanroom with terminal sterilization TRADITIONAL SAL 10-3 PHARMA - Inappropriate for complex biopharmaceuticals Probability of 1 in 1,000 of Pharma products finding a
Slide 49: Isolator technology: What are isolators?
SKAN Isolator technology: What are isolators? Isolators create a fully controlled Optimizing sterility to ensure patient safety aseptic environment Isolators facilitate meeting sterility standards for Isolators are completely sealed injectables and other complex molecule therapies systems, separatin
Slide 50: Isolator air handling (aseptic)
SKAN Isolator air handling (aseptic) 1 1 Air handling unit (AHU) 2 HEPA filter H14 2 3 4 3 Undirectional air flow 4 Return air by double windows SKAN Group AG Capital Markets Day 50 May 2025
Slide 51: Isolator for aseptic filling of toxic products
SKAN Isolator for aseptic filling of toxic products HEPA filtered inlet air from the HEPA filtered exhaust system 4 room is treated (temperature, 1 4 relative humidity, nitrogen 1 atmosphere) Monitoring of air velocity, differential pressure, temperature & relative humidity as well as particle count
Slide 52: Standardization to enable growth with less effort
SKAN Standardization to enable growth with less effort Examples Employees CAD template for toxic filling line Customized Several hundred hours less MED per each customized project Quality improvement Standardized = profitability, quality, Reduce 630 wire types to 99 lead time, scalability Better pur
Slide 53: Automation catalogue
SKAN Automation catalogue Currently 27 existing > to be continued May 2025 SKAN Group AG Capital Markets Day 53
Slide 54: spectra
SKAN spectra Sales - Calc PL – Config. Plan PL/MED – Profile-CH PL/MED – SAP-DE Profile-DE Electro Docu Automation - Config May 2025 SKAN Group AG Capital Markets Day 54
Slide 55: Spectra config tools
SKAN Spectra config tools Sales - Calc PL/MED – SAP-DE Profile-DE Automated Electro Docu Automation - Config May 2025 SKAN Group AG Capital Markets Day 55
Slide 56: GMP and Regulatory compliance
SKAN Group AG Capital Markets Day GMP and Regulatory compliance Richard Denk, Senior Consultant Aseptic Processing & Containment May 2025 56
Slide 57: GMP requirements for sterile injectables
SKAN GMP requirements for sterile injectables National and International Guidelines The Aseptic manufacturing for sterile have to be adapted and are inspected Products is highly regulated and monitored routinely from national and international Regulatory Authorities. May 2025 SKAN Group AG Capital M
Slide 58: GMP requirements for sterile injectables
SKAN GMP requirements for sterile injectables Current good manufacturing practice cGMP for sterile pharmaceutical products EU GMP Annex 1 – All EU countries PIC/s Annex 1 – 54 global Member states WHO Annex 2 – remaining world This is the first time that there is a global almost harmonized guideline
Slide 59: GMP requirements
SKAN GMP requirements Barrier and isolator systems Transfer as ebeam Automation as robotics May 2025 SKAN Group AG Capital Markets Day 59
Slide 60: Shaping GMP standards – Trusted by inspectors worldwide
Shaping GMP standards – SKAN Trusted by inspectors worldwide Sole industry presence at the 2024 EU/GMP Annex 1 training – reinforcing SKAN’s leading market position Training on Annex 1 implementation and robotics – concise, high-impact format with expert interaction Nearly 700 inspectors worldwide –
Slide 61: Shaping GMP standards – Trusted by inspectors worldwide
Shaping GMP standards – SKAN Trusted by inspectors worldwide Leveraging its deep expertise, SKAN conducted additional inspector trainings for In October 2025, SKAN hosts the official major health authorities GMP inspector training at its headquarters in Allschwil – strengthening its role as a truste
Slide 62: GMP requirements ATMPs cell and gene therapies
SKAN GMP requirements ATMPs cell and gene therapies Current good manufacturing Practice cGMP for ATMPs EU GMP annex 1 Part IV – All EU countries PIC/s Annex 2A – 54 global member states SKAN was involved as a service provider in the ISPE commenting team for the PIC/s Annex 2A for ATMPs May 2025 SKAN
Slide 63: Why is this a strategic advantage for SKAN – today and tomorrow?
SKAN Why is this a strategic advantage for SKAN – today and tomorrow? SKAN shares best practices with inspectors and regulators – demonstrating full alignment with current cGMP standards Being known by regulators worldwide enhances SKAN’s credibility – facilitating smoother inspections and enabling
Slide 64: Pre-approved services
SKAN Group AG Capital Markets Day Pre-approved services Thomas Zinn, Chief Officer Aseptic Manufacturing Services May 2025 64
Slide 65: Shift toward injectable biotech drugs drives need for aseptic process solutions
SKAN Shift toward injectable biotech drugs continues and drives need for aseptic process solutions 0% of top 10 drugs 50% of top 10 drugs 70% of top 10 drugs 2005 injectable dosage form 2020 injectable dosage form 2023 injectable dosage form Eylea Comirnaty Lipitor Zoloft Humira Humira Regeneron Pfi
Slide 66: Pre-approved services
SKAN Pre-approved services Focuses on technology driven Services and Offerings for aseptic fill-finish In the “Century of Biology”, precision molecules are developed faster with higher success rates Pharma manufacturers require faster, more flexible supply chain solutions Innovators depend on reliab
Slide 67: Pre-approved services commercialization planned in H2/2026
SKAN Pre-approved services commercialization planned in H2/2026 With Pre-Approved Services, SKAN will offer customers the Key data possibility to carry out their stability tests on our systems. Equipment: This will allow our customers to shorten the time-to-market At start: filling equipment with po
Slide 68: Accelerated go-to-market through pre-approved services
SKAN Accelerated go-to-market for our customers through pre-approved services – enabling faster access for patients Pre-approved services … speed up time to market and increase value Design & Manufacturing & Commissioning & Stability studies and Authority approval engineering assembling qualificatio
Slide 69: Filling system for RTU primary pack with isolator and ebeam
SKAN Filling system for RTU primary pack with isolator and ebeam Process • Aseptic operation in grade A isolator • Room grade C • ebeam for introduction of RTU containers • Inline sterile-filtration with PUPSIT • RTP alpha/beta port systems • Equipment • Single use: direct product contact filling-ki
Slide 70: Manufacturing system for novel ATMP manufacturing
SKAN Manufacturing system for novel ATMP manufacturing Flexible and state of the art design ▪ to adapt to customer process needs ▪ to overcome current compliance weaknesses ▪ to ensure robust supply to patients ATMP: Advanced therapy medicinal products May 2025 SKAN Group AG Capital Markets Day 70
Slide 71: Fully integrated digital landscape enables full leverage of manufacturing data
Fully integrated digital landscape enables full leverage SKAN of manufacturing data Digital Operational Technology (OT) Landscape ▪ All GMP relevant data in digital form (paperless manufacturing) ▪ Limits for process parameters checked by system (review by exception) ▪ Information in «OT landscape»
Slide 72: Questions & answers
Questions & answers May 2025 72
Slide 73: Wrap up
Wrap up May 2025 73
Slide 74: Pre-approved services
SKAN Pre-approved services May 2025 SKAN Group AG Capital Markets Day
Slide 75: Facility tour during lunch
SKAN Facility tour during lunch • Four different groups depending the color on your name tag • Start during lunch time • Tour takes about 20 minutes Enjoy your lunch! May 2025 SKAN Group AG Capital Markets Day 75
Slide 76: Together always one step ahead!
Together always one step ahead! May 2025 76